作者：
Daniel,Heudobler [1]
;
Florian,Luke [2]
;
Joachim,Hahn [3]
;
Matthias,Grube [3]
;
Pavla,Schlosser [3]
;
Stephan,Kremers [4]
;
Thomas,Sudhoff [5]
;
Jorg,Westermann [6]
;
Marie Luise,Hutter-Kronke [7]
;
Richard F,Schlenk [8]
;
Daniela,Weber [9]
;
Peter,Paschka [9]
;
Florian,Zeman [10]
;
Hartmut,Dohner [9]
;
Wolfgang,Herr [3]
;
Albrecht,Reichle [3]
;
Simone,Thomas [11]
作者单位：
University Hospital Regensburg, Department of Internal Medicine III, Hematology and Oncology, Germany; Bavarian Center for Cancer Research, University Hospital Regensburg, Regensburg. daniel.heudobler@ukr.de.
[1]
University Hospital Regensburg, Department of Internal Medicine III, Hematology and Oncology, Germany; Division of Personalized Tumor Therapy, Fraunhofer Institute for Toxicology and Experimental Medicine, Regensburg.
[2]
University Hospital Regensburg, Department of Internal Medicine III, Hematology and Oncology.
[3]
Caritaskrankenhaus Lebach, Department of Hematology/Oncology.
[4]
Klinikum Passau, Department Hematology and Oncology.
[5]
Charite- University Medical Center Berlin- Department of Hematology, Oncology and Tumor Immunology, Campus Virchow-Klinikum, Berlin.
[6]
Charite- University Medical Center Berlin- Department of Hematology, Oncology and Tumor Immunology, Campus Virchow-Klinikum, Berlin, Germany; University Hospital Ulm, Department of Internal Medicine III.
[7]
National Center of Tumor Diseases Trial Center, German Cancer Research Center and Heidelberg University Hospital, Heidelberg, Germany; Heidelberg University Hospital, Department of Internal Medicine V, Heidelberg.
[8]
University Hospital Ulm, Department of Internal Medicine III.
[9]
Center for Clinical Studies, University Hospital Regensburg, Regensburg.
[10]
University Hospital Regensburg, Department of Internal Medicine III, Hematology and Oncology, Germany; Leibniz Institute for Immunotherapy, Division of Genetic Immunotherapy, Regensburg.
[11]
DOI
10.3324/haematol.2023.283864
PMID
37881883
发布时间
2024-08-16
换一批
换一批
